AbCellera Biologics (NasdaqGS:ABCL) opened its Q1 2026 reporting season with recent quarterly revenue figures of US$44.9 million in Q4 2025 and a reported loss of US$8.9 million. This equates to basic EPS of US$0.03. On a trailing 12 month basis, revenue sits at US$75.1 million with EPS at US$0.49 and net income losses of US$146.4 million. Over the past year, the company has seen quarterly revenue move between US$4.2 million and US$44.9 million alongside quarterly EPS ranging from US$0.03 to US$0.19, with losses in each period. This puts the spotlight firmly on how quickly that top line can scale against a still heavy cost base. For investors, the story this quarter is less about revenue momentum in isolation and more about how quickly margins can close the gap between growth and ongoing losses.

See our full analysis for AbCellera Biologics.

With the headline numbers on the table, the next step is to see how this mix of revenue traction and persistent losses lines up with the prevailing market and community narratives around AbCellera Biologics.

Revenue swings and a rich 20.1x P/S tag

• On a trailing 12 month basis, AbCellera booked US$75.1 million of revenue while still trading on a 20.1x P/S ratio versus 3.5x for the broader US Life Sciences industry and 8.8x for peers, so the stock price is asking you to pay a much higher multiple for that revenue.
• Consensus narrative sees this strong revenue profile as a positive, with forecasts around 43% annual revenue growth. However, the combination of a much higher P/S multiple and ongoing losses raises the question of whether that growth and future margins are enough to justify a price that sits at US$4.95 against an analyst target of US$9.86.
  • Revenue over the last four reported quarters moved between US$4.2 million and US$44.9 million, showing that the current US$75.1 million trailing figure has come from very uneven quarterly contributions.
  • The higher 20.1x P/S ratio compared with the 3.5x industry average means any slowdown versus that 43% growth forecast would weigh more heavily here than at lower multiple peers.

Losses deepen while earnings forecasts decline 3.3%

• Over the trailing 12 months, AbCellera recorded a net loss of US$146.4 million and a basic EPS loss of US$0.49, and analysts in the cautious camp expect earnings to decline by about 3.3% per year over the next three years.
• Bears argue that this pattern of larger historical losses and projected earnings declines challenges the idea that heavy R&D spending will quickly translate into healthier margins, especially with quarterly net losses ranging from around US$8.9 million to US$57.1 million across 2025.
  • Trailing losses are described as having grown at about 63.9% per year over the last five years, which aligns with the bearish concern that the cost base is rising faster than revenue.
  • With the company expected to remain unprofitable over at least the next three years, the declining earnings forecast adds weight to the view that profitability is not yet within sight on the current trajectory.

On this view, skeptics point to the US$146.4 million trailing loss and projected earnings declines as key reasons to treat AbCellera as a higher risk, higher dispersion outcome story rather than a straightforward growth stock at today’s price. 🐻 AbCellera Biologics Bear Case

Pipeline expansion and bullish growth hopes

• The clinical and preclinical pipeline has expanded, with products in Phase I rising from 8 in Q3 2024 to 13 on a trailing 12 month basis by Q4 2025, while bullish analysts model revenue growth of 96.7% per year over the next three years despite the company reporting losses in every recent quarter.
• Bulls argue that more programs entering Phase I and the shift towards internal assets could eventually support higher margin revenue. They build on this by assuming revenue of US$250.3 million and earnings of US$35.6 million by around 2028 even though trailing figures still show US$75.1 million in revenue and a US$146.4 million loss today.
  • The bullish case also assumes a move from a loss of US$146.4 million to earnings of US$35.6 million, which is a very large swing in profitability relative to the current loss base.
  • To support that earnings jump, bullish models effectively require the stock to trade on a very high P/E multiple on those future earnings, while today investors only have the current US$4.95 share price and loss making profile to work with.

For investors who want to see how those aggressive revenue and earnings assumptions line up with the full bullish storyline around AbCellera’s pipeline, margins and royalties, it is worth reading the detailed bull argument in one place. 🐂 AbCellera Biologics Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for AbCellera Biologics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With the debate between bulls and bears laid out, the real question is where you land on this balance of risks and rewards. If you want to weigh the trade off yourself, start by reviewing the 1 key reward and 2 important warning signs that investors are focused on today 1 key reward and 2 important warning signs

Explore Alternatives

AbCellera pairs a high 20.1x P/S ratio with uneven revenue, persistent net losses of US$146.4 million and expectations that earnings remain negative for several years.

If you want ideas with clearer earnings trajectories and potentially less volatility, check out the 69 resilient stocks with low risk scores today and see which companies fit that profile.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.